Intelligent Bio Solutions Announces Closing of $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Rhea-AI Summary

Intelligent Bio Solutions (Nasdaq: INBS) closed a private placement priced at-the-market, selling 2,298,850 common shares (or pre-funded warrants) plus Series K-1 and K-2 warrants to purchase up to 2,298,850 shares each, for combined gross proceeds of approximately $10.0 million before fees.

The common shares (or pre-funded warrants) and associated warrants were sold at $4.35 per unit; the warrants have an exercise price of $4.10, are exercisable immediately, and will have a five-year term following effectiveness of a registration statement. Proceeds are intended for working capital, general corporate purposes and to fund a 510(k) FDA submission. The company agreed to file a resale registration within 10 days and use best efforts to have it declared effective within 45 days.

Positive

• Approximately $10.0 million gross capital raised
• Proceeds allocated to 510(k) FDA submission
• Registration filing committed within 10 days

Negative

• Potential issuance of up to 6,896,550 additional shares (shares + two warrant series)
• Gross proceeds reduced by placement agent fees and offering expenses
• Warrant overhang: warrants exercisable immediately with extended term tied to registration effectiveness

News Market Reaction

-17.21%

17 alerts

-17.21% News Effect

+5.9% Peak Tracked

-7.3% Trough Tracked

-$2M Valuation Impact

$9M Market Cap

0.4x Rel. Volume

On the day this news was published, INBS declined 17.21%, reflecting a significant negative market reaction. Argus tracked a peak move of +5.9% during that session. Argus tracked a trough of -7.3% from its starting point during tracking. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $9M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Private placement proceeds: $10.0 million Shares in placement: 2,298,850 shares Purchase price: $4.35 per share +5 more

8 metrics

Private placement proceeds $10.0 million Expected gross proceeds before fees from current private placement

Shares in placement 2,298,850 shares Common stock (or pre-funded warrants) sold in private placement

Purchase price $4.35 per share Combined price per share (or pre-funded warrant) plus associated warrants

Warrant exercise price $4.10 per share Exercise price for Series K-1 and K-2 warrants

Warrant term 5 years Term of Series K-1 and K-2 warrants after registration effectiveness

Quarterly revenue $1,111,797 Revenue for quarter ended Sep 30, 2025

Net loss $2,994,992 Net loss for quarter ended Sep 30, 2025

Cash and equivalents $1,660,105 Cash position as of Sep 30, 2025

Market Reality Check

Price: $8.69 Vol: Volume 1,944,719 is below...

low vol

$8.69 Last Close

Volume Volume 1,944,719 is below the 20-day average of 5,466,150 (relative volume 0.36). low

Technical Price $7.89 is trading below the $13.15 200-day moving average.

Peers on Argus

Peers in Medical Devices showed mixed, mostly modest moves, with names like AIMD...

Peers in Medical Devices showed mixed, mostly modest moves, with names like AIMD and NXL up 2.94% and 0.62%, while SINT fell 1.82%, suggesting INBS’s move was stock-specific rather than sector-driven.

Historical Context

5 past events · Latest: Dec 31 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 31	Private placement deal	Negative	+132.4%	Announced $10M at-the-market private placement with new K-series warrants.
Dec 31	Manufacturing partnership	Positive	+132.4%	New Syrma Johari partnership to cut costs and expand device capacity.
Dec 18	Strategic alliance	Positive	+18.4%	Vlepis partnership to extend non-invasive testing into wearables and consumer use.
Dec 12	Reverse stock split	Negative	-22.7%	1-for-10 reverse split implemented to support Nasdaq bid-price compliance.
Nov 20	Conference participation	Neutral	-6.3%	Planned presentation at Noble Capital Markets emerging growth conference.

Pattern Detected

Recent news has tied large positive moves to financing and strategic partnerships, while structural actions like the reverse split drew negative reactions.

Recent Company History

Over the last few months, INBS combined balance-sheet and strategic actions. A prior $10.0M private placement announcement and a manufacturing partnership on Dec 31, 2025 coincided with a strong +132.44% move. Earlier in December, a 1-for-10 reverse split and Nasdaq compliance steps were met with a -22.7% reaction. Additional partnerships and conference participation rounded out a period focused on funding, capacity, and visibility, to which today’s closing of the private placement directly relates.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-08-25

INBS has an active S-3/A shelf dated Aug 25, 2025, expiring Aug 25, 2028. It is not yet effective, and the company has used it at least once via a 424B5 filing on Sep 18, 2025, indicating pre-established capacity for future registered offerings.

Market Pulse Summary

The stock dropped -17.2% in the session following this news. A negative reaction despite the success...

Analysis

The stock dropped -17.2% in the session following this news. A negative reaction despite the successful closing of a $10.0M financing would fit concerns raised in recent filings about dilution and going-concern risk. The stock previously fell 22.7% around the reverse split, showing sensitivity to balance-sheet actions. Existing warrants and an active S-3/A signal continued capital needs, so additional equity issuance risk could reinforce pressure after financing news.

Key Terms

private placement, pre-funded warrants, warrants, registration statement, +3 more

7 terms

private placement financial

"announced the closing of its previously announced private placement with two healthcare"

A private placement is a way for companies to raise money by selling securities directly to a small group of investors instead of through a public offering. This process is often quicker and less regulated, making it similar to offering a special, exclusive investment opportunity to select individuals or institutions. For investors, it can provide access to unique investment options that are not available on public markets.

pre-funded warrants financial

"2,298,850 shares of common stock (or pre-funded warrants in lieu thereof)"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

warrants financial

"Series K-1 warrants to purchase up to an aggregate of 2,298,850 shares of common stock"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

registration statement regulatory

"a registration statement registering all warrant shares underlying the Series K-1 warrants"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

Nasdaq rules regulatory

"private placement with two healthcare focused institutional investors priced at-the-market under Nasdaq rules"

Nasdaq rules are a set of guidelines and requirements that companies must follow to be listed and remain on the Nasdaq stock exchange. These rules help ensure companies are transparent, financially healthy, and operate fairly, which is important for investors to trust the market and make informed decisions. Think of them as the standards that keep the marketplace honest and organized.

510(k) submission regulatory

"including funding our 510(k) submission with the FDA for our non-invasive"

A 510(k) submission is a regulatory packet sent to the U.S. Food and Drug Administration showing a medical device is substantially similar to an already-allowed device so it can be marketed without a full, new safety review. For investors, clearance via 510(k) cuts time and cost to bring a device to market and reduces regulatory risk—think of it as proving a new model is close enough to a trusted one to sell it more quickly.

FDA regulatory

"funding our 510(k) submission with the FDA for our non-invasive Intelligent"

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

AI-generated analysis. Not financial advice.

NEW YORK, Jan. 02, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the closing of its previously announced private placement with two healthcare focused institutional investors priced at-the-market under Nasdaq rules of 2,298,850 shares of common stock (or pre-funded warrants in lieu thereof), Series K-1 warrants to purchase up to an aggregate of 2,298,850 shares of common stock and Series K-2 warrants to purchase up to an aggregate of 2,298,850 shares of common stock, at a combined purchase price of $4.35 per share of common stock (or pre-funded warrant) and associated Series K-1warrants and Series K-2 warrants, for expected gross proceeds to INBS of approximately $10.0 million, before deducting placement agent fees and other offering expenses payable by the Company. The Series K-1warrants and Series K-2 warrants will have an exercise price of $4.10 per share of common stock and will be exercisable immediately upon issuance. The Series K-1 warrants and Series K-2 warrants will each have a term of five years following the date a registration statement registering all warrant shares underlying the Series K-1 warrants and Series K-2 warrants is declared effective by the United States Securities and Exchange Commission (the “SEC”).

Harry Simeonidis, President and CEO of INBS, commented, “We welcome the continued support from our investors as we intend to use the proceeds of this private placement for working capital and general corporate purposes, including funding our 510(k) submission with the FDA for our non-invasive Intelligent Fingerprinting Drug Screening System and furthering our international market expansion.”

Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for the private placement.

The offer and sale of the foregoing securities were made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Under an agreement with the investors, the Company agreed to file an initial registration statement with the SEC covering the resale of the shares of common stock issued to the investors (including the shares of common stock issuable upon the exercise of the warrants) no later than 10 calendar days following the date of the agreement and to use its best efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event no later than 45 days after the date of such agreement.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. 

About Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.

For more information, visit: http://www.ibs.inc/.

Forward-Looking Statements:

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s intended use of proceeds from the private placement, ability to develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions' public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Company Contact:

Intelligent Bio Solutions Inc.
info@ibs.inc

Investor & Media Contact:

Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com

FAQ

How much did INBS raise in the January 2, 2026 private placement?

INBS raised approximately $10.0 million in gross proceeds before fees and expenses.

What securities were sold in INBS private placement on January 2, 2026?

The sale included 2,298,850 common shares (or pre-funded warrants) plus Series K-1 and K-2 warrants to buy up to 2,298,850 shares each.

What is the INBS warrant exercise price and term from the private placement?

The Series K-1 and K-2 warrants have an exercise price of $4.10 and a five-year term following effectiveness of the related registration statement.

How will INBS use the proceeds from the $10.0 million private placement?

Proceeds are intended for working capital, general corporate purposes and to fund a 510(k) submission with the FDA.

When will INBS file the resale registration statement related to the private placement?

The company agreed to file an initial registration statement within 10 calendar days and to use best efforts to have it effective within 45 days.